Tori Kinamon encountered sepsis when she was a freshman in college. A previously healthy Division 1 collegiate gymnast, she acquired a severe Methicillin-resistant Staphylococcus aureus (MRSA) in her left hamstring, which led to sepsis. She had eight surgeries in two weeks, spent over one month in the hospital, and then five months recovering at home. Following her hospitalization, she made it her mission to reframe her traumatic experience in a meaningful way to benefit others. As such, she devoted herself to research, studying topics including antimicrobial resistance (AMR), MRSA colonization amongst collegiate athletes, and musculoskeletal infections. Most recently, she completed an Oak Ridge Institute for Science and Education (ORISE) fellowship at the U.S. Food and Drug Administration in which she derived novel endpoints for antibacterial clinical trials. A current medical student at Duke University School of Medicine, she remains committed to patient advocacy and education for AMR and sepsis. She is a member of the WHO Task Force of AMR Survivors, and the Antibacterial Resistance Leadership Group.